Atlas Trials

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Clinical trial NCT06210971 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06210971
Sponsor
Hebei Medical University Fourth Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Rectal Cancer
Start date
2024-02-01
Primary completion
2025-09-30
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.